Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage III Prostate Cancer AJCC v8: full-pipeline trial registry
19 of 29 indexed Stage III Prostate Cancer AJCC v8 trials are currently recruiting.
Corpus placement: #552 of 28,707 conditions by registered trial count.
29 US clinical trials · 19 currently recruiting · #552 of 28,707 conditions by registered trial count
Stage III Prostate Cancer AJCC v8: 29 US clinical trials tracked, 19 recruiting.
Stage III Prostate Cancer AJCC v8 is the subject of 29 registered US clinical trials on ClinicalTrials.gov, 19 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 6 of these trials.
Enrollment posture brief
Registry condition stage-iii-prostate-cancer-ajcc-v8
OPEN 19 | RECR 66% | LATE 7 | EARLY 10 | RANK #552 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Hematopoietic and Lymphoid System Neoplasm (66% recruiting · 32 trials)
Stage III Prostate Cancer AJCC v8 lists 19 open slots (66% of 29 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage III Prostate Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage III Prostate Cancer AJCC v8 is recruiting above its size-band peers.
19 of 29 indexed trials (65.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage III Prostate Cancer AJCC v8 research.
Mayo Clinic accounts for 6 of 29 trials (20.7%). 12 distinct sponsors appear on at least one study for this condition label.
-
Typical Stage III Prostate Cancer AJCC v8 enrolment sits around 80 participants.
Median target enrolment is 80 among the 29 trials that report a genuine target (sentinel values excluded). 16 of those (55.2%) plan for fewer than 100 participants.
-
Stage III Prostate Cancer AJCC v8 research is mostly interventional.
28 interventional and 1 observational studies make up this index (96.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
29 total, page 1 of 1
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NRG Oncology
NCT05946213
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NRG Oncology
NCT04134260
Vitamin D for Prostate Endocrine Therapy
University of Rochester
NCT05838716
Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy
City of Hope Medical Center
NCT05869682
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
NCT04947254
Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial
Jonsson Comprehensive Cancer Center
NCT07276438
Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer
Mayo Clinic
NCT06325046
Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation
Thomas Jefferson University
NCT05487846
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic
NCT06205316
Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of Localized Prostate Cancer, ILLUSION Trial
Jonsson Comprehensive Cancer Center
NCT06995053
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
University of California, Davis
NCT06173362
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Emory University
NCT06650579
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
Jonsson Comprehensive Cancer Center
NCT04945642
Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
Mayo Clinic
NCT06389786
Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
Mayo Clinic
NCT07073794
Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer
Emory University
NCT04725903
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
Mayo Clinic
NCT07025369
Feasibility and Effect of Wrapping Nerves With a Multi-Layer Perinatal Tissue Allograft During Prostatectomy
Mayo Clinic
NCT06940271
Golf Recreational Exercise for Enhanced Survivorship in Prostate Cancer Survivors
University of Southern California
NCT06500169
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
NCT04513717
Lifestyle Behavior Influences Among African American Patients With Stage 0-III Prostate Cancer Survivors and Their Partners
M.D. Anderson Cancer Center
NCT04189770
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
NCT03987386
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
University of Washington
NCT04777071
RElugolix VErsus LeUprolide Cardiac Trial
Emory University
NCT05320406
Watchful Living in Improving Quality of Life in Participants With Localized Prostate Cancer on Active Surveillance and Their Partners
M.D. Anderson Cancer Center
NCT03575832
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
NCT03582475
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
Roswell Park Cancer Institute
NCT03899987
Lifestyle Intervention for the Reduction of Prostate Cancer Disparities Among African Americans
M.D. Anderson Cancer Center
NCT04215029
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
NCT04037254
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 8 |
| Phase 3 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage III Prostate Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage III Prostate Cancer AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage III Prostate Cancer AJCC v8 page
29 registered trials, 19 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 19 Stage III Prostate Cancer AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mayo Clinic sponsors the most Stage III Prostate Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage III Prostate Cancer AJCC v8 condition card totals 29 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.